|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we show that the oncogenic BRAF somatic mutation p.Val600Glu (V600E) in developing neurons underlies intrinsic epileptogenicity in ganglioglioma, one of the leading causes of intractable epilepsy<sup>2</sup>.
|
30224756 |
2018 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we show that the oncogenic BRAF somatic mutation p.Val600Glu (V600E) in developing neurons underlies intrinsic epileptogenicity in ganglioglioma, one of the leading causes of intractable epilepsy<sup>2</sup>.
|
30224756 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In GGs alone, high expression of LC3B revealed significant correlation with BRAF V600E mutation and temporal location (P=0.020; P=0.015), while Beclin-1 showed no correlation with them (P>0.05).
|
28667867 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In GGs alone, high expression of LC3B revealed significant correlation with BRAF V600E mutation and temporal location (P=0.020; P=0.015), while Beclin-1 showed no correlation with them (P>0.05).
|
28667867 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In both GGs and DNTs, the presence of BRAF V600E mutation was significantly associated with the expression of CD34, phosphorylated ribosomal S6 protein (pS6; marker of mTOR pathway activation) in dysplastic neurons and synaptophysin (P < 0.05).
|
23941441 |
2014 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In both GGs and DNTs, the presence of BRAF V600E mutation was significantly associated with the expression of CD34, phosphorylated ribosomal S6 protein (pS6; marker of mTOR pathway activation) in dysplastic neurons and synaptophysin (P < 0.05).
|
23941441 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, although spinal gangliogliomas display histologic and clinical features similar to their supratentorial counterparts, they show a relatively low frequency of BRAF(V600E) mutations, alteration otherwise common in hemispheric and brain stem gangliogliomas.
|
26826417 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, although spinal gangliogliomas display histologic and clinical features similar to their supratentorial counterparts, they show a relatively low frequency of BRAF(V600E) mutations, alteration otherwise common in hemispheric and brain stem gangliogliomas.
|
26826417 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, DNT shared with PXA and GG, BRAF(V600E) mutation and/or CD34 expression, which represent molecular markers for these tumors, and we recommend searching for CD34 expression and BRAF(V600E) mutation in all DNT, especially the non-specific forms.
|
23442159 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, DNT shared with PXA and GG, BRAF(V600E) mutation and/or CD34 expression, which represent molecular markers for these tumors, and we recommend searching for CD34 expression and BRAF(V600E) mutation in all DNT, especially the non-specific forms.
|
23442159 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the third case, where the interval spanned multiple decades, the GG was found to be positive for both BRAF p.V600E immunohistochemistry (IHC) and for the KIAA1549-BRAF fusion.
|
31147230 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the third case, where the interval spanned multiple decades, the GG was found to be positive for both BRAF p.V600E immunohistochemistry (IHC) and for the KIAA1549-BRAF fusion.
|
31147230 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells.
|
23435618 |
2013 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells.
|
23435618 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PA and GG BRAF V600E-mutant had significantly lower rADCmean (p < 0.001) and rADCmin (p < 0.001) values than wild type, regardless of tumor histology and location.
|
31667545 |
2020 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PA and GG BRAF V600E-mutant had significantly lower rADCmean (p < 0.001) and rADCmin (p < 0.001) values than wild type, regardless of tumor histology and location.
|
31667545 |
2020 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.
|
27799506 |
2016 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma.
|
27799506 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The p.Val600Glu was found in 14/75 grade II GG.No EP were BRAF mutated.
|
31673897 |
2019 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The p.Val600Glu was found in 14/75 grade II GG.No EP were BRAF mutated.
|
31673897 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The high mutation frequencies in pleomorphic xanthoastrocytomas, gangliogliomas and extra-cerebellar pilocytic astrocytomas implicate BRAF (V600E) mutation as a valuable diagnostic marker for these rare tumor entities.
|
21274720 |
2011 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The high mutation frequencies in pleomorphic xanthoastrocytomas, gangliogliomas and extra-cerebellar pilocytic astrocytomas implicate BRAF (V600E) mutation as a valuable diagnostic marker for these rare tumor entities.
|
21274720 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data suggest that BRAF V600E can predict the regrowth rate of brainstem gangliogliomas after microsurgery, and a BRAF V600E-targeted therapeutic may be a promising early intervention measure for patients who harbour BRAF V600E mutation after microsurgery.
|
28986151 |
2017 |
|
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data suggest that BRAF V600E can predict the regrowth rate of brainstem gangliogliomas after microsurgery, and a BRAF V600E-targeted therapeutic may be a promising early intervention measure for patients who harbour BRAF V600E mutation after microsurgery.
|
28986151 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Three gangliogliomas with BRAF p.V600E mutation had concurrent CDKN2A homozygous deletion and one additionally harbored a subclonal mutation in PTEN.
|
29880043 |
2018 |